Anakinra not checked

Swedish Orphan Biovitrum

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
None yet
 
Trials
14 active
23 in total · 18 in the EU
Targets
 

What this is

How it works
Interleukin-1 Receptor Antagonist FDA class
Tested for
Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
Main trialPhase 3
“A study to demonstrate efficacy and safety of anakinra in pediatric and adult Japanese patients with Still's disease (Systemic juvenile idiopathic arthritis \[SJIA\] and Adult-onset Still's disease \[AOSD\]).”In the company’s words, NCT05814159 on ClinicalTrials.gov
Other names
Kineret

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials23

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 10 Dec 2025 A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
Phase 4Withdrawn 30 Aug 2027 A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
Phase 4Withdrawn 30 Sep 2028 An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD)
Phase 3Terminated 13 Feb 2019 A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)
Phase 2/3Terminated 13 Nov 2020 Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.
Phase 3Authorised not given Therapeutic approach in Colchicine-resistant Recurrent pEricarditis in children: an open-label randomized trial comparing Anakinra vs sTEroids
Phase 2Ended not given Immunomodulatory effects of dexamethasone, tocilizumab and anakinra during experimental human endotoxemia: the DEDICATE-LPS study
Phase 3Authorised not given Randomized controlled trial in patients on long-term colchicine with colchicine-resistant familial Mediterranean fever (FMF) to evaluate the efficacy of on-demand Anakinra treatment for painful attacks in patients who refuse continuous daily therapy (KIN-ATTACK-FMF).
Phase 2/3Authorised not given Safety and efficacy of anakinra treatment for patients with persistent respiratory symptoms post acute covid and immune system activation: the PRECISION double-blind, randomized clinical trial
Phase 2Ended not given A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutaneous administration of anakinra in patients with cystic fibrosis (ANAKIN)
Phase 2Ended not given PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease
Phase 3Ended not given ANA4CKD - Randomized multicenter double-blind controlled trial comparing anakinra to prednisone for gout flare in patients with chronic kidney disease stage 4-5 or kidney transplantation
Phase 2Authorised not given Deciphering IL-1 mediated inflammation for the targeted treatment of dilated cardiomyopathy.
Phase 2Ended not given Myocarditis Therapy with IL-1 inhibitor (MYTH-1): a double-blind, phase IIa, placebo controlled, randomized clinical trial to evaluate the efficacy and safety of anakinra in addition to standard of care for the treatment of virus-negative myocarditis.
Phase 3Authorised not given ANACOMP. A RANDOMIZED PHASE III MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF ANAKINRA VERSUS INTRAVENOUS IMMUNOGLOBULIN (IVIG) RETREATMENT, IN PATIENTS WITH KAWASAKI DISEASE WHO FAILED TO RESPOND TO INITIAL STANDARD IVIG TREATMENT
Phase 2Authorised not given Anakinra in Cerebral haemorrhage to Target secondary Injury resulting from Neuroinflammation - a phase II clinical trial
Phase 2Authorised not given Efficacy and safety of anakinra in non-COVID-19 related ARDS. ESKA study.
Phase 4Authorised not given Biomarker-guided treatment-and-stop-strategy for recombinant IL-1receptor antagonist (anakinra) in patients with systemic Juvenile Idiopathic Arthritis
Phase 2Authorised not given PALETTE - Adaptive platform trial for personalisation of sepsis treatment in children and adults: a multi-national, treatable traits-guided, adaptive, exploratory, bayesian basket trial
Phase 3Authorised not given ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS. ANAPEM
Phase 2Authorised not given Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment
Phase 2Authorised not given THRILL: Treat Hyperinflammation in child oncology study - A single arm, historically controlled, open label phase II study on the efficacy and safety of the recombinant interleukin (IL)-1R antagonist anakinra in pediatric cancer patients admitted to the intensive care with sepsis and signs of hyperinflammation
Phase 1/2Authorised not given IL-1β blockade to prevent Immunothrombosis in recipients of a Pancreatic Organ (ILIPO)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Anakinra

Following is part of Solo: you see every change to Anakinra the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in